Within the group of the recognized Polish experts, based on the data from the PL-ACS Registry, for the first time in the world we confirmed that the upfront combination lipid-lowering therapy is superior to statin monotherapy for all-cause mortality in patients with ACS. These results suggest that in high-risk patients, such an approach, rather than a stepwise therapy approach, should be recommended.

JOIN US FOR THE 10TH ANNIVERSARY MEETING OF ILEP!
We are proud to invite you to a very special event – the 10th Anniversary Meeting of the International Lipid Expert Panel (ILEP), taking place on June 5–6, 2025, at